News
Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.
GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback